T cell responses to whole SARS coronavirus in humans.
Identifieur interne : 001A55 ( PubMed/Curation ); précédent : 001A54; suivant : 001A56T cell responses to whole SARS coronavirus in humans.
Auteurs : Chris Ka-Fai Li [Royaume-Uni] ; Hao Wu ; Huiping Yan ; Shiwu Ma ; Lili Wang ; Mingxia Zhang ; Xiaoping Tang ; Nigel J. Temperton ; Robin A. Weiss ; Jason M. Brenchley ; Daniel C. Douek ; Juthathip Mongkolsapaya ; Bac-Hai Tran ; Chen-Lung Steve Lin ; Gavin R. Screaton ; Jin-Lin Hou ; Andrew J. Mcmichael ; Xiao-Ning XuSource :
- Journal of immunology (Baltimore, Md. : 1950) [ 1550-6606 ] ; 2008.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps antiviraux (immunologie), Cytokines (immunologie), Femelle, Humains, Lymphocytes T CD8+ (immunologie), Lymphocytes auxiliaires Th2 (immunologie), Mâle, Mémoire immunologique, Protéine de membrane-1 associée au lysosome (immunologie), Protéome (immunologie), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (mortalité), Vaccins antiviraux (immunologie), Virus du SRAS (immunologie), Études de cohortes.
- MESH :
- immunologie : Anticorps antiviraux, Cytokines, Lymphocytes T CD8+, Lymphocytes auxiliaires Th2, Protéine de membrane-1 associée au lysosome, Protéome, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- mortalité : Syndrome respiratoire aigu sévère.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Mémoire immunologique, Études de cohortes.
English descriptors
- KwdEn :
- Adult, Antibodies, Viral (immunology), CD8-Positive T-Lymphocytes (immunology), Cohort Studies, Cytokines (immunology), Female, Humans, Immunologic Memory, Leukocyte Common Antigens (immunology), Lysosomal-Associated Membrane Protein 1 (immunology), Male, Middle Aged, Proteome (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (mortality), Th2 Cells (immunology), Tumor Necrosis Factor Receptor Superfamily, Member 7 (immunology), Viral Vaccines (immunology).
- MESH :
- chemical , immunology : Antibodies, Viral, Cytokines, Leukocyte Common Antigens, Lysosomal-Associated Membrane Protein 1, Proteome, Tumor Necrosis Factor Receptor Superfamily, Member 7, Viral Vaccines.
- immunology : CD8-Positive T-Lymphocytes, SARS Virus, Severe Acute Respiratory Syndrome, Th2 Cells.
- mortality : Severe Acute Respiratory Syndrome.
- Adult, Cohort Studies, Female, Humans, Immunologic Memory, Male, Middle Aged.
Abstract
Effective vaccines should confer long-term protection against future outbreaks of severe acute respiratory syndrome (SARS) caused by a novel zoonotic coronavirus (SARS-CoV) with unknown animal reservoirs. We conducted a cohort study examining multiple parameters of immune responses to SARS-CoV infection, aiming to identify the immune correlates of protection. We used a matrix of overlapping peptides spanning whole SARS-CoV proteome to determine T cell responses from 128 SARS convalescent samples by ex vivo IFN-gamma ELISPOT assays. Approximately 50% of convalescent SARS patients were positive for T cell responses, and 90% possessed strongly neutralizing Abs. Fifty-five novel T cell epitopes were identified, with spike protein dominating total T cell responses. CD8(+) T cell responses were more frequent and of a greater magnitude than CD4(+) T cell responses (p < 0.001). Polychromatic cytometry analysis indicated that the virus-specific T cells from the severe group tended to be a central memory phenotype (CD27(+)/CD45RO(+)) with a significantly higher frequency of polyfunctional CD4(+) T cells producing IFN-gamma, TNF-alpha, and IL-2, and CD8(+) T cells producing IFN-gamma, TNF-alpha, and CD107a (degranulation), as compared with the mild-moderate group. Strong T cell responses correlated significantly (p < 0.05) with higher neutralizing Ab. The serum cytokine profile during acute infection indicated a significant elevation of innate immune responses. Increased Th2 cytokines were observed in patients with fatal infection. Our study provides a roadmap for the immunogenicity of SARS-CoV and types of immune responses that may be responsible for the virus clearance, and should serve as a benchmark for SARS-CoV vaccine design and evaluation.
DOI: 10.4049/jimmunol.181.8.5490
PubMed: 18832706
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A55
Links to Exploration step
pubmed:18832706Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">T cell responses to whole SARS coronavirus in humans.</title><author><name sortKey="Li, Chris Ka Fai" sort="Li, Chris Ka Fai" uniqKey="Li C" first="Chris Ka-Fai" last="Li">Chris Ka-Fai Li</name><affiliation wicri:level="1"><nlm:affiliation>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name></author><author><name sortKey="Yan, Huiping" sort="Yan, Huiping" uniqKey="Yan H" first="Huiping" last="Yan">Huiping Yan</name></author><author><name sortKey="Ma, Shiwu" sort="Ma, Shiwu" uniqKey="Ma S" first="Shiwu" last="Ma">Shiwu Ma</name></author><author><name sortKey="Wang, Lili" sort="Wang, Lili" uniqKey="Wang L" first="Lili" last="Wang">Lili Wang</name></author><author><name sortKey="Zhang, Mingxia" sort="Zhang, Mingxia" uniqKey="Zhang M" first="Mingxia" last="Zhang">Mingxia Zhang</name></author><author><name sortKey="Tang, Xiaoping" sort="Tang, Xiaoping" uniqKey="Tang X" first="Xiaoping" last="Tang">Xiaoping Tang</name></author><author><name sortKey="Temperton, Nigel J" sort="Temperton, Nigel J" uniqKey="Temperton N" first="Nigel J" last="Temperton">Nigel J. Temperton</name></author><author><name sortKey="Weiss, Robin A" sort="Weiss, Robin A" uniqKey="Weiss R" first="Robin A" last="Weiss">Robin A. Weiss</name></author><author><name sortKey="Brenchley, Jason M" sort="Brenchley, Jason M" uniqKey="Brenchley J" first="Jason M" last="Brenchley">Jason M. Brenchley</name></author><author><name sortKey="Douek, Daniel C" sort="Douek, Daniel C" uniqKey="Douek D" first="Daniel C" last="Douek">Daniel C. Douek</name></author><author><name sortKey="Mongkolsapaya, Juthathip" sort="Mongkolsapaya, Juthathip" uniqKey="Mongkolsapaya J" first="Juthathip" last="Mongkolsapaya">Juthathip Mongkolsapaya</name></author><author><name sortKey="Tran, Bac Hai" sort="Tran, Bac Hai" uniqKey="Tran B" first="Bac-Hai" last="Tran">Bac-Hai Tran</name></author><author><name sortKey="Lin, Chen Lung Steve" sort="Lin, Chen Lung Steve" uniqKey="Lin C" first="Chen-Lung Steve" last="Lin">Chen-Lung Steve Lin</name></author><author><name sortKey="Screaton, Gavin R" sort="Screaton, Gavin R" uniqKey="Screaton G" first="Gavin R" last="Screaton">Gavin R. Screaton</name></author><author><name sortKey="Hou, Jin Lin" sort="Hou, Jin Lin" uniqKey="Hou J" first="Jin-Lin" last="Hou">Jin-Lin Hou</name></author><author><name sortKey="Mcmichael, Andrew J" sort="Mcmichael, Andrew J" uniqKey="Mcmichael A" first="Andrew J" last="Mcmichael">Andrew J. Mcmichael</name></author><author><name sortKey="Xu, Xiao Ning" sort="Xu, Xiao Ning" uniqKey="Xu X" first="Xiao-Ning" last="Xu">Xiao-Ning Xu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18832706</idno><idno type="pmid">18832706</idno><idno type="doi">10.4049/jimmunol.181.8.5490</idno><idno type="wicri:Area/PubMed/Corpus">001A55</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A55</idno><idno type="wicri:Area/PubMed/Curation">001A55</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">T cell responses to whole SARS coronavirus in humans.</title><author><name sortKey="Li, Chris Ka Fai" sort="Li, Chris Ka Fai" uniqKey="Li C" first="Chris Ka-Fai" last="Li">Chris Ka-Fai Li</name><affiliation wicri:level="1"><nlm:affiliation>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford</wicri:regionArea></affiliation></author><author><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name></author><author><name sortKey="Yan, Huiping" sort="Yan, Huiping" uniqKey="Yan H" first="Huiping" last="Yan">Huiping Yan</name></author><author><name sortKey="Ma, Shiwu" sort="Ma, Shiwu" uniqKey="Ma S" first="Shiwu" last="Ma">Shiwu Ma</name></author><author><name sortKey="Wang, Lili" sort="Wang, Lili" uniqKey="Wang L" first="Lili" last="Wang">Lili Wang</name></author><author><name sortKey="Zhang, Mingxia" sort="Zhang, Mingxia" uniqKey="Zhang M" first="Mingxia" last="Zhang">Mingxia Zhang</name></author><author><name sortKey="Tang, Xiaoping" sort="Tang, Xiaoping" uniqKey="Tang X" first="Xiaoping" last="Tang">Xiaoping Tang</name></author><author><name sortKey="Temperton, Nigel J" sort="Temperton, Nigel J" uniqKey="Temperton N" first="Nigel J" last="Temperton">Nigel J. Temperton</name></author><author><name sortKey="Weiss, Robin A" sort="Weiss, Robin A" uniqKey="Weiss R" first="Robin A" last="Weiss">Robin A. Weiss</name></author><author><name sortKey="Brenchley, Jason M" sort="Brenchley, Jason M" uniqKey="Brenchley J" first="Jason M" last="Brenchley">Jason M. Brenchley</name></author><author><name sortKey="Douek, Daniel C" sort="Douek, Daniel C" uniqKey="Douek D" first="Daniel C" last="Douek">Daniel C. Douek</name></author><author><name sortKey="Mongkolsapaya, Juthathip" sort="Mongkolsapaya, Juthathip" uniqKey="Mongkolsapaya J" first="Juthathip" last="Mongkolsapaya">Juthathip Mongkolsapaya</name></author><author><name sortKey="Tran, Bac Hai" sort="Tran, Bac Hai" uniqKey="Tran B" first="Bac-Hai" last="Tran">Bac-Hai Tran</name></author><author><name sortKey="Lin, Chen Lung Steve" sort="Lin, Chen Lung Steve" uniqKey="Lin C" first="Chen-Lung Steve" last="Lin">Chen-Lung Steve Lin</name></author><author><name sortKey="Screaton, Gavin R" sort="Screaton, Gavin R" uniqKey="Screaton G" first="Gavin R" last="Screaton">Gavin R. Screaton</name></author><author><name sortKey="Hou, Jin Lin" sort="Hou, Jin Lin" uniqKey="Hou J" first="Jin-Lin" last="Hou">Jin-Lin Hou</name></author><author><name sortKey="Mcmichael, Andrew J" sort="Mcmichael, Andrew J" uniqKey="Mcmichael A" first="Andrew J" last="Mcmichael">Andrew J. Mcmichael</name></author><author><name sortKey="Xu, Xiao Ning" sort="Xu, Xiao Ning" uniqKey="Xu X" first="Xiao-Ning" last="Xu">Xiao-Ning Xu</name></author></analytic><series><title level="j">Journal of immunology (Baltimore, Md. : 1950)</title><idno type="eISSN">1550-6606</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Viral (immunology)</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>Cohort Studies</term><term>Cytokines (immunology)</term><term>Female</term><term>Humans</term><term>Immunologic Memory</term><term>Leukocyte Common Antigens (immunology)</term><term>Lysosomal-Associated Membrane Protein 1 (immunology)</term><term>Male</term><term>Middle Aged</term><term>Proteome (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (mortality)</term><term>Th2 Cells (immunology)</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 7 (immunology)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiviraux (immunologie)</term><term>Cytokines (immunologie)</term><term>Femelle</term><term>Humains</term><term>Lymphocytes T CD8+ (immunologie)</term><term>Lymphocytes auxiliaires Th2 (immunologie)</term><term>Mâle</term><term>Mémoire immunologique</term><term>Protéine de membrane-1 associée au lysosome (immunologie)</term><term>Protéome (immunologie)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (mortalité)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS (immunologie)</term><term>Études de cohortes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Cytokines</term><term>Leukocyte Common Antigens</term><term>Lysosomal-Associated Membrane Protein 1</term><term>Proteome</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 7</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Cytokines</term><term>Lymphocytes T CD8+</term><term>Lymphocytes auxiliaires Th2</term><term>Protéine de membrane-1 associée au lysosome</term><term>Protéome</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD8-Positive T-Lymphocytes</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Th2 Cells</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Immunologic Memory</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Mémoire immunologique</term><term>Études de cohortes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Effective vaccines should confer long-term protection against future outbreaks of severe acute respiratory syndrome (SARS) caused by a novel zoonotic coronavirus (SARS-CoV) with unknown animal reservoirs. We conducted a cohort study examining multiple parameters of immune responses to SARS-CoV infection, aiming to identify the immune correlates of protection. We used a matrix of overlapping peptides spanning whole SARS-CoV proteome to determine T cell responses from 128 SARS convalescent samples by ex vivo IFN-gamma ELISPOT assays. Approximately 50% of convalescent SARS patients were positive for T cell responses, and 90% possessed strongly neutralizing Abs. Fifty-five novel T cell epitopes were identified, with spike protein dominating total T cell responses. CD8(+) T cell responses were more frequent and of a greater magnitude than CD4(+) T cell responses (p < 0.001). Polychromatic cytometry analysis indicated that the virus-specific T cells from the severe group tended to be a central memory phenotype (CD27(+)/CD45RO(+)) with a significantly higher frequency of polyfunctional CD4(+) T cells producing IFN-gamma, TNF-alpha, and IL-2, and CD8(+) T cells producing IFN-gamma, TNF-alpha, and CD107a (degranulation), as compared with the mild-moderate group. Strong T cell responses correlated significantly (p < 0.05) with higher neutralizing Ab. The serum cytokine profile during acute infection indicated a significant elevation of innate immune responses. Increased Th2 cytokines were observed in patients with fatal infection. Our study provides a roadmap for the immunogenicity of SARS-CoV and types of immune responses that may be responsible for the virus clearance, and should serve as a benchmark for SARS-CoV vaccine design and evaluation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18832706</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1550-6606</ISSN><JournalIssue CitedMedium="Internet"><Volume>181</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of immunology (Baltimore, Md. : 1950)</Title><ISOAbbreviation>J. Immunol.</ISOAbbreviation></Journal><ArticleTitle>T cell responses to whole SARS coronavirus in humans.</ArticleTitle><Pagination><MedlinePgn>5490-500</MedlinePgn></Pagination><Abstract><AbstractText>Effective vaccines should confer long-term protection against future outbreaks of severe acute respiratory syndrome (SARS) caused by a novel zoonotic coronavirus (SARS-CoV) with unknown animal reservoirs. We conducted a cohort study examining multiple parameters of immune responses to SARS-CoV infection, aiming to identify the immune correlates of protection. We used a matrix of overlapping peptides spanning whole SARS-CoV proteome to determine T cell responses from 128 SARS convalescent samples by ex vivo IFN-gamma ELISPOT assays. Approximately 50% of convalescent SARS patients were positive for T cell responses, and 90% possessed strongly neutralizing Abs. Fifty-five novel T cell epitopes were identified, with spike protein dominating total T cell responses. CD8(+) T cell responses were more frequent and of a greater magnitude than CD4(+) T cell responses (p < 0.001). Polychromatic cytometry analysis indicated that the virus-specific T cells from the severe group tended to be a central memory phenotype (CD27(+)/CD45RO(+)) with a significantly higher frequency of polyfunctional CD4(+) T cells producing IFN-gamma, TNF-alpha, and IL-2, and CD8(+) T cells producing IFN-gamma, TNF-alpha, and CD107a (degranulation), as compared with the mild-moderate group. Strong T cell responses correlated significantly (p < 0.05) with higher neutralizing Ab. The serum cytokine profile during acute infection indicated a significant elevation of innate immune responses. Increased Th2 cytokines were observed in patients with fatal infection. Our study provides a roadmap for the immunogenicity of SARS-CoV and types of immune responses that may be responsible for the virus clearance, and should serve as a benchmark for SARS-CoV vaccine design and evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chris Ka-fai</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Huiping</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shiwu</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lili</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mingxia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Temperton</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Robin A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Brenchley</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Douek</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Mongkolsapaya</LastName><ForeName>Juthathip</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Bac-Hai</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chen-lung Steve</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Screaton</LastName><ForeName>Gavin R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Jin-lin</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>McMichael</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiao-Ning</ForeName><Initials>XN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0400720</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U137881015</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z99 AI999999</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Immunol</MedlineTA><NlmUniqueID>2985117R</NlmUniqueID><ISSNLinking>0022-1767</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052118">Lysosomal-Associated Membrane Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018127">Tumor Necrosis Factor Receptor Superfamily, Member 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D017493">Leukocyte Common Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="Y">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017493" MajorTopicYN="N">Leukocyte Common Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052118" MajorTopicYN="N">Lysosomal-Associated Membrane Protein 1</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018127" MajorTopicYN="N">Tumor Necrosis Factor Receptor Superfamily, Member 7</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18832706</ArticleId><ArticleId IdType="pii">181/8/5490</ArticleId><ArticleId IdType="pmc">PMC2683413</ArticleId><ArticleId IdType="mid">NIHMS109289</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.181.8.5490</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Infect Dis. 2000 Sep;182 Suppl 1:S74-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10944487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2004 Apr;4(4):308-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15057789</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Feb;77(3):2081-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12525643</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2004 Jul 1;104(1):200-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15016646</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1969 Apr;89(4):422-34</Citation><ArticleIdList><ArticleId IdType="pubmed">4305198</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1999 May;5(5):518-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10229228</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2004 Nov 23;171(11):1349-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15557587</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Mar;11(3):411-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15757556</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Nov;11(11):1730-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16318725</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2005 Dec;5(12):917-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16322745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2006 Aug 15;177(4):2138-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16887973</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2006 Aug;12(8):972-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16862156</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2006 Oct;12(10):1203-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16964257</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation><ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Sep;3(9):e411; author reply e415</Citation><ArticleIdList><ArticleId IdType="pubmed">17002511</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2006;1:e24</Citation><ArticleIdList><ArticleId IdType="pubmed">17183651</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2007;25:443-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17243893</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):1063-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17327210</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jun;81(11):6079-88</Citation><ArticleIdList><ArticleId IdType="pubmed">17392374</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17620608</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Aug;81(16):8692-706</Citation><ArticleIdList><ArticleId IdType="pubmed">17537853</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2008 Apr;133(1):74-87</Citation><ArticleIdList><ArticleId IdType="pubmed">17451830</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2008 Apr;133(1):20-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17499378</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1761-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12781533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1158-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15031782</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2001 Feb;75(3):1339-47</Citation><ArticleIdList><ArticleId IdType="pubmed">11152507</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001A55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:18832706
|texte= T cell responses to whole SARS coronavirus in humans.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18832706" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |